During the Senate hearing, Sanofi Pasteur Asia Pacific head Thomas Triomphe said Dengvaxia is safe and effective and there should be no cause for scare, although Sanofi's November 29 announcement said Dengvaxia could cause "severe dengue" in persons who had not have not had the infection before they got the vaccine. Its clinical data showed there is risk of dengue before and after getting the vaccine.